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ABSTRACT
Background: Zinc plays a pivotal role in the pathogenesis of many
diseases and in body growth. Preterm neonates have high zinc re-
quirements.
Objective: The objective of the study was to investigate the efficacy
of zinc supplementation in reducing morbidity and mortality in
preterm neonates and to promote growth.
Design: This was a prospective, double-blind, randomized con-
trolled study of very-low-birth-weight preterm neonates randomly
allocated on the seventh day of life to receive (zinc group) or not
receive (control group) oral zinc supplementation. Total prescribed
zinc intake ranged from 9.7 to 10.7 mg/d in the zinc group and from
1.3 to 1.4 mg/d in the placebo control group. The main endpoint
was the rate of neonates with $1 of the following morbidities: late-
onset sepsis, necrotizing enterocolitis, bronchopulmonary dysplasia,
periventricular leucomalacia, and retinopathy of prematurity. Sec-
ondary outcomes were mortality and body growth.
Results: We enrolled 97 neonates in the zinc group and 96 in the
control group. Morbidities were significantly lower in the zinc
group (26.8% compared with 41.7%; P = 0.030). The occurrence
of necrotizing enterocolitis was significantly higher in the con-
trol group (6.3% compared with 0%; P = 0.014). Mortality risk
was higher in the placebo control group (RR: 2.37; 95% CI:
1.08, 5.18; P = 0.006). Daily weight gain was similar in the zinc
(18.2 6 5.6 g $ kg21 $ d21) and control (17.0 6 8.7 g $ kg21 $ d21)
groups (P = 0.478).
Conclusion: Oral zinc supplementation given at high doses reduces
morbidities and mortality in preterm neonates. This trial was regis-
tered in the Australian New Zealand Clinical Trial Register as
ACTRN12612000823875. Am J Clin Nutr 2013;98:1468–74.
INTRODUCTION
Zinc is a structural component of hormones, nucleotides, and
proteins. It is required for the production of a wide variety of
enzymes involved in essential metabolic patterns (ie, protein
synthesis, nucleic acid metabolism, immune function, and or-
ganogenesis) (1–3). Zinc is crucial for the development of the
brain, respiratory and intestinal tracts in pre- and postnatal life
(1, 4–11).
Preterm neonates have lower zinc reserves than term infants
because w60% of fetal zinc is acquired during the third tri-
mester of pregnancy (3). Preterm infants are also less efficient at
absorbing and retaining zinc for growth (3). Adequate absorp-
tion may be compromised by limited intake, immature digestive
and absorptive processes; excessive endogenous losses occur
secondary to either poorly regulated secretion or interference
with reabsorption (3). Thus, premature neonates have relatively
high dietary zinc requirements (12–14). However, studies on
zinc homeostasis in neonates have produced somewhat con-
flicting results regarding zinc requirements and optimal daily
intakes (1–3, 14). There is a wealth of evidence that zinc, at
different doses, has a positive influence on morbidity, mortality,
and growth in infants and children (15–17). Recent trials have
suggested that high doses of zinc as co-treatment against in-
fections early in the life (18, 19). In this trial we aimed to in-
vestigate the efficacy of high zinc doses to reduce morbidity and
mortality and promote growth in preterm neonates.
SUBJECTS AND METHODS
Study design and period
A double-blind, single-center, randomized, placebo-controlled
trial was conducted between January 2009 and May 2012. The
study design was approved by the ethics committee of our Center
(#0901). Written informed consent was obtained from the parents
of the infants enrolled in the study.
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All very-low-birth-weight (VLBW)4 neonates (birth weight:
401–1500 g or a gestational age of 24 to 32 wk), consecutively
observed in a neonatal intensive care unit, were considered el-
igible for the study. Exclusion criteria were as follows: con-
genital or maternal infections, immunodeficiency, malformations,
syndromes, genetic defects, evidence of infection, and necro-
tizing enterocolitis (NEC) diagnosed before enrollment, criti-
cally ill conditions (defined as a blood pH ,6.8 or hypoxia with
persistent bradycardia for $1 h), and hospitalization for ,1 wk.
Intervention, randomization, and blinding
On the seventh day of life, the neonates enrolled were ran-
domly allocated to 2 study groups: group 1 (zinc group), who
received a commercially available multivitamin product in drops
containing zinc (Previtamin 0; DUPI), and group 2 (placebo
control group), who received a similar multivitamin preparation
without zinc (Previtamin; DUPI). The composition of the mul-
tivitamin products used in this study is reported in Table 1. Daily
doses of zinc and vitamins were prescribed irrespective of body
weight. The 2 multivitamin preparations were provided in
identical bottles without indication of group identity or content.
Each bottle was labeled with a unique serial number according
to the randomization list; this information was not available to
the investigators until the data had been obtained, entered in the
database, and analyzed by a blinded statistician. After ran-
domization, nurses blinded to the study aims administered the
assigned preparation as drops, once daily, 2 h after feeding. The
supplement was given again to subjects who vomited within
15 min after the administration. All episodes of vomiting and
other adverse events were reported on the clinical chart. Vom-
iting episodes within 15 min from administration/number of
doses administered per patient were recorded. Compliance was
measured by the rate of number of doses administered/number
of doses prescribed, as documented by nurses in the clinical
chart. The supplement assigned was discontinued at discharge or
at 42 wk postconceptual age.
Outcome measures
The main endpoint was the rate of neonates presenting, during
the hospitalization period, at least one of the followingmorbidities:
late-onset sepsis, NEC, bronchopulmonary dysplasia (BPD),
periventricular leucomalacia (PVL), and retinopathy of prema-
turity (ROP). Secondary outcomes were mortality and growth.
Data collection
Data regarding gestational age, weight at birth, mode of de-
livery, multiple birth, sex, Apgar score, Critical Risk Index for
Babies score (20), presence of respiratory distress syndrome,
patent ductus arteriosus (PDA), mode and duration of mechanical
ventilation, start of enteral feeding, time to reach full enteral
feeding, breast milk use, presence and duration of central vas-
cular access, time-to-discharge, occurrence of late-onset sepsis,
NEC, BPD, PVL, intraventricular hemorrhage, and ROP were
collected by researchers not in charge of the clinical management
of the participants. Diagnosis of late-onset sepsis, NEC, BPD,
PVL, and ROP was performed according to standardized criteria
(21–25) by physicians unaware of the study design and aims.
Discharge was decided by the same physicians with the use of
criteria indicated by the American Academy of Pediatrics (26).
The patients’ study courses are reported in Figure 1.
Feeding protocol and vitamin supplementation
Enteral feeding was started on the first day of life at 10 mL $
kg21 $ d21 divided into 8 feeds by using preterm formula in all
stable infants, as previously described (27). When available,
maternal milk was administered. Human milk fortification was
added when full enteral feeding was achieved. Aspirate residual
from an orogastric tube and abdominal aspect were checked
before each feeding. The total amount of gastric residue was
calculated daily. In the absence of signs of feeding intolerance in
the previous 24 h, enteral nutrition was increased daily by 10–20
mL/kg. Enteral nutrition was discontinued in the case of er-
ythematic abdominal wall, absence of bowel sounds, blood in
the stools, or bile or blood in aspirates associated with a radio-
logic marker of NEC-Bell stage $II (22). Parenteral nutrition
was maintained through a central vascular access in all infants to
ensure adequate intake of fluids, electrolytes, and nutrients until
full enteral feeding was reached (28). Neonates receiving total
parenteral nutrition received intravenously 1 mg Zn/d, starting
from day 7 of life. Vitamins and zinc prescriptions during the
study period are reported in Table 2 (29). Iron was supple-
mented orally according to recommendations (30).
Statistics
To demonstrate a 20% reduction in morbidity in subjects
receiving zinc with 85% power and a type 1 error = 0.05 (2-tailed
test), a minimum sample size of 100 patients for each group was
required. The Kolmogorov-Smirnov test was used to determine
whether variables were normally distributed. For continuous
variables, groups were compared by using the test of equality of
means, the Mann-Whitney U test, and the Kruskal-Wallis test.
The chi-square test and Fisher’s exact test were used for cate-
gorical variables. For 2 related dichotomous variables, the
McNemar test was used to detect differences between study
TABLE 1
Composition of the multivitamin preparations used in the study1
Group 1 (zinc) Group 2 (control)
Energy (kcal) 0.05 0.12
Vitamin A (mg) 480 750
Vitamin C (mg) 60 60
Vitamin E (mg) 6 6
Folic acid (mg) 120 100
Vitamin D3 (IU) 800 800
Vitamin B-12 (mg) 0.6 0.6
Zinc (mg) 9 0
1Data refer to a daily dose of vitamins and zinc sulfate provided with
commercially available products used in the trial. Doses reported were main-
tained for the entire duration of the study and were not modified when the
neonates gained weight.
4Abbreviations used: BPD, bronchopulmonary dysplasia; NEC, necrotiz-
ing enterocolitis; PDA, patent ductus arteriosus; PVL, periventricular leuco-
malacia; RCT, randomized controlled trial; ROP, retinopathy of prematurity;
VLBW, very low birth weight.
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groups. We performed a multivariate analysis using binary lo-
gistic regression analysis to evaluate whether morbidity was
influenced by gestational age, modality of delivery, multiple
birth, body weight, sex, Apgar score at 5 min, or study group
assignment. The level of significance for all statistical tests was
2-sided (P , 0.05). Statistical analysis was performed, per in-
tention-to-treat, by a statistician blinded to patient group as-
signment, by using SPSS version 16.0 for Windows (SPSS Inc).
RESULTS
A total of 203 VLBWneonates were considered eligible for the
study. Ten subjects were excluded because of malformations (n =
4), early-onset sepsis (n = 3), and corioamnionitis (n = 3). Eight
of these neonates died. Five subjects were lost to follow-up
because they required surgery for PDA and ROP. A total of 188
VLBW neonates completed the study protocol (Figure 2). The
main clinical and demographic characteristics of the study
population are reported in Table 3.
No difference was observed in the rate of neonates with sepsis,
BPD, PVL, or ROP between groups (Table 4), but the risk of
developing at least one of the abovementioned morbidities was
significantly reduced (OR: 0.513; 95% CI: 0.280, 0.939; P = 0.030)
in subjects receiving zinc supplementation (Table 4). NEC was
observed only in neonates in the control group (Table 4). The
rate of breast milk use was not significantly different between
neonates with (50%) or without (15%) NEC (P = 0.166).
Mortality risk after enrollment was higher in neonates who
received placebo than in those who received zinc supplemen-
tation at a high dose (17 of 96 compared with 5 of 97; RR: 2.37;
95% CI: 1.08, 5.18; P = 0.006). No significant differences were
observed when the causes of death in the 2 groups were com-
pared (sepsis: 9 of 17 compared with 3 of 5; intraventricular
hemorrhage: 4 of 17 compared with 1 of 5; PDA: 3 of 17
compared with 1 of 5; NEC: 1 of 17 compared with 0 of 5). The
duration of hospitalization was similar in the 2 groups (group 1:
59 6 31 d; group 2: 49 6 35 d; P = 0.181). Body weight at
discharge was higher in the zinc group than in the placebo group
(2208 6 501 g compared with 1889 6 639 g; P = 0.001). Daily
weight gain was similar in the zinc (18.2 6 5.6 g $ kg21 $ d21)
and control (17.0 6 8.7 g $ kg21 $ d21; P = 0.478) groups.
Binary logistic regression analysis showed that morbidity
was influenced by male sex (OR: 2.291; 95% CI: 1.147, 4.577;
P = 0.019), Apgar score at 5 min (OR: 0.545; 95% CI: 0.370,
FIGURE 1. Study design.
TABLE 2
Daily doses of vitamins and zinc in the 2 study populations1
When receiving total parenteral
nutrition
When full enteral feeding was reached2
(enteral nutrition .110 kcal/kg)
Preterm-formula fed Fortified breast-milk fed
Group 1 (zinc) Group 2 (control) Group 1 (zinc) Group 2 (control) Group 1 (zinc) Group 2 (control)
Vitamin A (mg) 780 1050 573 843 833 1104
Vitamin C (mg) 75 75 75 75 79 73
Vitamin E (mg) 6.8 6.8 7 7 9 9
Folic acid (mg) 146 126 160 140 161 141
Vitamin D3 (IU) 800 800 1000 1000 1000 1000
Vitamin B-12 (mg) 0.8 0.8 0.8 0.8 0.9 0.9
Iron (mg)3 0 0 1.7 1.7 0.04 0.04
Zinc (mg) 10 1 10.3 1.3 10.4 1.4
1Doses were calculated including the amounts in parenteral nutrition or enteral nutrition formula and oral multivitamin supplements.
2Data are expressed according to the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition, where 100
kcal corresponds to a minimum energy intake of 110 kcal/kg body wt (29).
3Doses reported in the table refer to the content of iron in parenteral and enteral nutrition; iron was further supplemented orally at 2–5 mg $ kg21 $ d21
starting from 4 wk of life in all neonates according to recommendations (30).
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0.803; P = 0.002), and assignment to the zinc group (OR: 0.500;
95% CI: 0.249, 0.998; P = 0.048). Occurrence of vomiting after
treatment was similar in the zinc (2.4 6 4.0%) and the control
(2.0 6 3.7%) groups (P = 0.396). No adverse events associated
with the administration of multivitamin products containing zinc
or not were observed. Compliance was similar between groups
(all of the doses prescribed were administered).
DISCUSSION
Our findings indicate a significant reduction in morbidity and
mortality associated with the use of high-dose zinc supplements
in the diet of VLBW neonates. These results agree with those of
previous studies that support an advantage of zinc supplementation
early in life. Twelve randomized controlled trials (RCTs) were
conducted in subjects aged ,28 d of life (13, 15, 19, 31–39).
Seven studies had a double-blind design, and most of these trials
enrolled slightly preterm or small-for-gestational-age neonates
(13, 15, 19, 32, 34, 37, 38). Three studies, including infants with
a birth weight ,1500 g (31, 36, 39), investigated the effect of
zinc on body growth and neurodevelopment. Although positive,
the conclusions of these studies were limited by the small number
of observations. The 2 largest trials reported a reduced morbidity
and mortality associated with zinc use early in life (15, 38). None
of these trials enrolled VLBW preterm neonates. A systematic
review (16) on the effect of neonatal zinc supplementation on
preventing morbidity and mortality evaluated 3 trials including
low-birth-weight infants receiving zinc within the first month of
FIGURE 2. Flow of neonates through the study. Mean (6SD) age at discharge: group 1, 59 6 31 d; group 2, 49 6 35 d.
TABLE 3
Main demographic and clinical characteristics of the study population1
Group 1 (zinc; n = 97) Group 2 (control; n = 96) P
Body weight at birth (g) 1114 (1056, 1172)2 1033 (969, 1097) 0.066
Gestational age (wk) 28 (28, 29) 28 (27, 29) 0.720
Cesarean delivery [n (%)] 92 (94.8) 87 (90.6) 0.258
Twins [n (%)] 23 (23.7) 18 (18.8) 0.399
Male [n (%)] 37 (38.1) 43 (44.8) 0.349
Apgar score at 1 min 5.3 (4.93, 5.74) 5.3 (4.98, 5.67) 0.969
Apgar score at 5 min 7.5 (7.28, 7.67) 7.5 (7.31, 7.69) 0.880
Critical Risk Index for Babies 2.1 6 1.33 2.2 6 1.7 0.114
Respiratory distress syndrome [n (%)] 92 (94.8) 93 (96.9) 0.721
Invasive mechanical ventilation [n (%)] 46 (47.4) 56 (58.3) 0.129
Patent ductus arteriosus requiring pharmacotherapy [n (%)] 35 (36.1) 34 (35.4) 0.923
Intraventricular hemorrhage, grade $3 [n (%)] 8 (8.2) 11 (11.5) 0.454
Start of enteral nutrition (h) 3 (1.6, 4.0) 2 (1.8, 2.2) 0.176
Time to reach full enteral feeding (d) 17 (15.3, 19.8) 14 (11.6, 16.7) 0.440
Breast milk/total enteral nutrition at enrollment (%) 45.5 (39.2, 51.8) 46.9 (40.2, 53.5) 0.760
Breast milk/total enteral nutrition at discharge (%) 30.8 (24.9, 36.6) 27.5 (20.8, 34.3) 0.470
1 For continuous variables, groups were compared by using the test of equality of means, the Mann-Whitney U test, and the Kruskal-Wallis test. The chi-
square test and Fisher’s exact test were used for categorical variables. For 2 related dichotomous variables, the McNemar test was used to detect differences
between study groups.
2Mean; 95% CI in parentheses (all such values).
3Mean 6 SD (all such values).
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life for $14 d (32, 34, 38). They concluded that the available
data were too limited to evaluate the efficacy of zinc on long-
term morbidity and mortality and that the 3 trials analyzed were
not adequately powered to evaluate these outcomes. In addition,
all of the trials were conducted in developing countries, and 2
were from India, which limited the generalization of findings to
industrialized countries. Finally, the predictors for heterogeneity
were not investigated because of the small number of trials, and
information on exclusive or predominant breastfeeding status
was available only at the time of initiation of the study.
The dietary recommendations for preterm neonates suggest
1.1–2 mg $ kg Zn21 $ d21 (29). We used higher zinc doses; the
use of zinc doses above the dietary guidance level is an emerging
research area in pediatric nutrition (10, 16). Many studies suggest
that 10–20 mg Zn/d is able to limit the risk of infections in
children (40–42). Total zinc intake in the zinc group ranged from
9.7 to 10.7 mg/d. High doses in preterm neonates seem justified
because of the lower stores at birth, the higher requirements for
growth, and potentially other stress factors present during pre-
maturity (16). In a large trial, Sazawal et al (15) showed a re-
duction in mortality in the first 9 mo of life in an RCT that
enrolled full-term small-for-gestational-age infants who re-
ceived oral zinc supplementation at high doses (5 mg/d). A dose
of 10 mg/d was adopted in other studies involving neonates early
in life to prevent bacterial infections (18, 19). Our study was the
first trial to use high doses of zinc in VLBW neonates. Zinc
requirements are higher in the first days of life than subsequently.
We administered zinc irrespective of body weight to provide
higher dose in early life. The intakes of zinc in the control group
are at the low end of the recommended range (29). Our results
suggest that the recommended intakes of zinc meet the metabolic
requirement of preterm neonates but may be insufficient to affect
morbidity, and, finally, that only high doses of zinc may exert a
real pharmacologic effect. No side effects were observed in our
study, as previously shown by others (1–3). Further studies should
be carried out to establish the optimal dose of zinc in this par-
ticular population.
The morbidities analyzed in this study are heterogeneous and
have a multifactorial pathogenesis. Zinc plays an important role
at multiple levels and may interfere with the pathogenesis of
many neurologic, respiratory, and intestinal complications typi-
cally affecting preterm neonates (4–11). This aspect may explain
how a single nutrient may affect the occurrence of different diseases.
In addition, zinc participates in the response to environmental
injury determined by oxidative stress and free radical–mediated
diseases (1–3). This is probably the route by which zinc in-
terferes with the development of many complications involving
the brain and respiratory and intestinal tracts by exerting a pro-
tective effect (3–8). The most evident beneficial effect was ob-
served against NEC. This finding could be attributable to the
numerous positive activities of zinc at the intestinal level. These
include regulation of intestinal permeability, epithelial cell
growth and differentiation, and immune response (9, 22). The
mechanisms of action of zinc were not investigated in this trial.
Further studies are necessary to better define the metabolic ef-
fects elicited by high zinc doses at different tissue levels and
specifically during NEC development.
The administration of zinc early in life, when the organism is in
rapid development, has a key role in promoting growth and
differentiation (4–11). Zinc is essential for insulin-like growth
factor I and growth hormone receptor gene expression and is
crucial to ensure normal grow in early life (43). We found an
improvement in weight gain at discharge in infants receiving
high zinc supplementation. Several RCTs analyzed the effect of
zinc on growth in the first months of life (13, 31, 32, 36, 37, 39),
but no conclusive results were obtained. Diet supplementation
with zinc may limit extrauterine growth retardation (2). The
potential benefit of higher zinc intake on growth was suggested
by a cross-sectional study showing a direct correlation between
daily weight gain and intestinal zinc absorption with a daily
intake of w3 mg (44). However, these authors suggested that
additional studies should be performed to assess the potential
benefit of higher zinc intakes. Our results support the potential
utility of zinc supplementation, not only to limit the most
common morbidities of prematurity, but also to drive the optimal
development of body growth and functions.
Our findings, although encouraging, should nevertheless be
interpreted with consideration of some limitations. Because we
evaluated a specific population of VLBW neonates, the con-
clusions may not be necessarily extended to subjects with dif-
ferent gestational ages or body weights. Although we observed
interesting results on the occurrence of NEC, this study was not
powered to demonstrate the efficacy of zinc in preventing this
condition. We also observed differences in the use of breast milk
when comparing neonates with or without NEC. Although not
statistically significant, this difference confirms the protective
TABLE 4
Neonatal morbidities observed in the 2 study groups1
Group 1 (zinc; n = 97) Group 2 (control; n = 96) P
Late-onset sepsis [n (%)] 16 (16.5) 12 (12.5) 0.431
Necrotizing enterocolitis [n (%)]2 0 (0) 6 (6.3) 0.014
Bronchopulmonary dysplasia [n (%)]3 10 (10.3) 15 (15.6) 0.272
Periventricular leucomalacia [n (%)] 3 (3.1) 9 (9.4) 0.071
Retinopathy of prematurity4 0 (0.0) 3 (3.17) 0.121
Patients with $1 of the conditions listed above [n (%)] 26 (26.8) 40 (41.7) 0.030
1 For continuous variables, groups were compared by using the test of equality of means, the Mann-Whitney U test, and the Kruskal-Wallis test. The chi-
square test and Fisher’s exact test were used for categorical variables. For 2 related dichotomous variables, the McNemar test was used to detect differences
between study groups.
2Necrotizing enterocolitis Bell stage .2 (22).
3Oxygen therapy at 36 wk of postconceptional age (23).
4 Stage .2 (25).
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role of breast milk on the risk of NEC (45). Serum concentrations
of zinc or other vitamins were not measured to avoid adjunctive
procedures and blood collections in preterm infants at high risk of
iatrogenic anemia and to minimize handling (46, 47). The high
dose of zinc used during this trial was established on the basis of
previous evidence (18, 19, 40–42), whenever the zinc in the
placebo group was administered at the low end of the recom-
mended range. Further studies are probably advocated to es-
tablish the optimal dose of zinc in this particular population. We
used 2 multivitamin formulations with slight differences in some
nutrients other than zinc (eg, folic acid and vitamin A). To the
best of our knowledge there is no evidence that postnatal folic
acid supplementation influences the occurrence of morbidities
and survival in VLBW neonates. Previous RCTs on parenteral
vitamin A supplementation (48) were unable to demonstrate a re-
duction in the mortality rate of preterm infants. One RCT evalu-
ated the efficacy of vitamin A given orally in neonates (49). In this
study, vitamin A supplementation failed to reduce mortality and
morbidity (49). Finally, to the best of our knowledge this was the
first time a dose of w10 mg Zn/d was administered to preterm
neonates. Further studies should be performed to evaluate the
potential efficacy of different doses of oral zinc supplementation.
In conclusion, this was the first study to investigate the efficacy
of zinc supplementation in reducing morbidity and mortality in
VLBW preterm neonates during hospitalization. A high zinc
intake could be considered a safe and useful nutritional in-
tervention in early life. Further studies should be performed to
shed light on the mechanisms underlying the effects observed.
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